BMS delivers sales, profit growth in Plavix's final quarter

All eyes are on new and forthcoming drugs as Bristol-Myers Squibb ($BMY) reports a 12% increase in first-quarter profits, fueled by rising sales of cancer drugs Yervoy and Sprycel and hepatitis B treatment Baraclude. Report